[Surveillance for various injectable antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa in hyogo prefecture]. 2005

Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
Department of Clinical Laboratory, Hyogo Prefectural Amagasaki Hospital.

Antimicrobial susceptibility of 13 antimicrobial drugs for the injection and O-group antigen serotype were measured for the 766 Pseudomonas aeruginosa strains that had been isolated from various clinical materials in 29 facilities in the Hyogo prefecture from April to September in 2004. Metallo beta-lactamase detection was also performed. The antimicrobial activity was excellent in the order of GM, MEPM, AMK, CPFX and CAZ. Susceptible category of the breakpoint by National Committee for Clinical Laboratory Standards (CLSI/NCCLS) was excellent in the order of AMK, GM, PIPC, CZOP, and MEPM. As for the susceptibility of Carbapenem, it is confirmed that susceptible of MEPM was detected in 47 strains (36.4%) and metallo beta-lactamase producing P. aeruginosa was in 3 strains (0.4%) and multi-drug resistant P. aeruginosa were in 7 strains only (0.9%) among 129 strains of the IPM resistant (I or R). The results of the susceptibility test against P. aeruginosa were different in each facility, but there were several stocks having the identical O-antigen serotype and anti-biogram pattern in some facilities. The nosocomial infection measures including the antimicrobial propriety use are necessary.

UI MeSH Term Description Entries
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D001618 beta-Lactamases Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins. beta-Lactamase,beta Lactamase,beta Lactamases
D012703 Serotyping Process of determining and distinguishing species of bacteria or viruses based on antigens they share. Serotypings
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance

Related Publications

Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
May 1987, Gaoxiong yi xue ke xue za zhi = The Kaohsiung journal of medical sciences,
Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
March 1995, The Canadian veterinary journal = La revue veterinaire canadienne,
Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
June 2004, Saudi medical journal,
Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
February 2001, The Japanese journal of antibiotics,
Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
August 2007, The Journal of antimicrobial chemotherapy,
Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
December 2003, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
March 2006, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
January 2014, GMS hygiene and infection control,
Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
July 2008, The Journal of urology,
Tomomi Koufuku, and Tomomi Okazaki, and Miki Hujiwara, and Masayo Adati, and Sumika Yamanouti, and Emiko Kanou, and Yuko Nakajima, and Tsuneo Hayashi, and Yoka Hospital, and Shigeo Kitayama, and Shohiro Kinoshita
May 2003, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!